FlowSens® is more affordable, innovative and offers faster turnaround times than its competing solutions
MOUNTAIN VIEW, California, Oct. 26, 2015 /PRNewswire/ -- Based on its recent analysis of the market for contrast auto-injector computed tomography (CT) imaging modality, Frost & Sullivan recognizes Guerbet with the 2015 European Frost & Sullivan Award for New Product Innovation. Guerbet's syringe-free auto-injector, FlowSens®, is the first commercial injector to employ hydraulic technology in combination with syringe-free injection systems for the delivery of contrast media during medical imaging diagnosis. Even at a modest estimate of seven to nine examinations a day, FlowSens® can generate a cost savings of up to 10-12 percent annually on the materials usage. This would be a significant advantage for the European healthcare industry, which is grappling with slimmer budgets and economic uncertainties.
According to Frost & Sullivan, the unique design of FlowSens® helps lower the cost of disposables by at least 15-20 percent. When compared to conventional auto-injectors or power injectors, it generates extra savings of 8 percent on material expenses and up to 3 percent on personnel costs.
"Guerbet's pioneering syringe-free injector technology endows it with certain strategic advantages over its competitors," said Frost & Sullivan Senior Research Analyst Srikanth Kompalli. "Firstly, it broke new grounds in contrast media injectors by merging hydraulic technology with a syringe-free injection method to give the caregiver complete control over the delivery of the contrast agent with intuitive usage and safeguarding of procedures at every stage of the injection."
The FlowSens® CT injector features two soft bags for mono- or dual-liquid contrast injections, a complete range of associated disposables (class IIa, CE-marked) and services, and is compatible with all CT contrast media and saline solutions. Additionally, it comes with a variety of disposable components for individual patient use and works with pre-filled injector bags and vials.
Furthermore, FlowSens® is compatible with ScanBag® and all types of contrast agents available in the market. The system possesses three modes of protocol programming for the injection site, with a memory capacity of 20 libraries, 4,000 protocols and 24,000 injections.
The fluid used is infused at pressures of up to 305 PSI (21 bar), and it can be either floor or ceiling mounted, which releases up to 220 mL of liquid volume per delivery phase. The injector can be adapted to single- or multi-patient markets and mono- or bi-liquid uses, providing superior results.
For developing an affordable CT auto-contrast injector that boasts high-quality outcomes, with an intuitive usage and safeguarding of procedures at every stage of the injection, Frost & Sullivan is pleased to present Guerbet with the 2015 European Frost & Sullivan Award for New Product Innovation.
Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which, in turn, increases customer acquisition and overall market penetration potential.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.
Guerbet is a pioneer in the contrast agent field, with nearly 90 years' experience, and is the only pharmaceutical group dedicated to medical imaging worldwide. It offers a comprehensive range of XRay, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve the diagnosis and treatment of patients. To discover new products and ensure future growth, Guerbet invests heavily in R&D, spending around 9% of its sales each year. Guerbet (GBT) is listed on NYSE Euronext Paris (Segment B – Mid Caps) and generated revenue of €409 million in 2014. It had a total workforce of 1,461 employees at 31 December 2014.
For more information about Guerbet, please go to www.guerbet.com
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
P: 210. 247.3870
SOURCE Frost & Sullivan